Bicara Therapeutics Inc. Common Stock (BCAX)vsNovartis AG ADR (NVS)

BCAX

Bicara Therapeutics Inc. Common Stock

NASDAQ

$25.89

-3.68%

HEALTHCARE · Cap: $1.85B

NVS

Novartis AG ADR

NYSE

$158.83

-0.25%

HEALTHCARE · Cap: $290.96B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

BCAX

Avoid

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.0

Piotroski: 1/9Altman Z: 7.03

NVS

Buy

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BCAX.

NVSSignificantly Overvalued (-70.9%)

Margin of Safety

-70.9%

Fair Value

$92.73

Current Price

$158.83

$66.10 premium

UndervaluedFair: $92.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BCAX2 strengths · Avg: 10.0/10

Debt/EquityHealth

0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth

7.0310/10

Safe zone — low bankruptcy risk

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability

22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality

$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

BCAX4 concerns · Avg: 3.5/10

Revenue GrowthGrowth

0.0%4/10

0.0% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$1.85B3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

NVS4 concerns · Avg: 3.3/10

Revenue GrowthGrowth

0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.183/10

Elevated debt levels

PEG RatioValuation

4.152/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BCAX

The strongest argument for BCAX centers on Debt/Equity, Altman Z-Score.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bear Case : BCAX

The primary concerns for BCAX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 26/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bicara Therapeutics Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

BCAX vs VRTX BCAX vs REGN BCAX vs ARGX BCAX vs RVMD BCAX vs ALNY NVS vs VRTX NVS vs REGN NVS vs ARGX NVS vs RVMD NVS vs ALNY

Want to dig deeper into these stocks?

Full BCAX Analysis →Full NVS Analysis →